Drug
Ensifentrine clinical trials
Also written RPL554.
- studies test it
- 17
- open now
- 1
- in phase 3
- 5
- first study started
- 2014
Keep track of what changes. Save the ensifentrine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
17 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 2 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 10
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 0
Verona Pharma plc (11) · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA (3) · Nuance Pharma (shanghai) Co., Ltd (2) · Merck Sharp & Dohme LLC (1)
Often tested with
Tested in the same studies.
Glycopyrrolate (2) · Tiotropium (1) · Albuterol (1) · Ipratropium (1)
Studies
Open first, then newest update. How each study uses ensifentrine is read from its arms, and is right about nine times in ten.
Testing it · 17
- Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3)Not yet recruitingPhase 3Merck Sharp & Dohme LLCNCT07874815Written as Ensifentrine
- Effect of Ensifentrine on Sputum Markers of Inflammation in COPDActive, not recruitingPhase 2Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USANCT05270525Written as Ensifentrine
- Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212)CompletedPhase 2Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USANCT07016412Written as Ensifentrine 3 mg
- A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary DiseaseCompletedPhase 2Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USANCT07132983Written as Ensifentrine 3 mg
- A Study to Evaluate the Efficacy and Safety of Ensifentrine for 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseCompletedPhase 3Nuance Pharma (shanghai) Co., LtdNCT05743075Written as Ensifentrine
- Effect of Ensifentrine Treatment on CAT ScoreCompletedPhase 3Verona Pharma plcNCT06460493Written as Ensifentrine 3 mg twice daily
- A Study of RPL554 in Patients With Cystic FibrosisCompletedPhase 2Verona Pharma plcNCT02919995Written as RPL554
- A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPDCompletedPhase 3Verona Pharma plcNCT04535986Written as Ensifentrine
- A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPDCompletedPhase 3Verona Pharma plcNCT04542057Written as Ensifentrine
- A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Nebulized Ensifentrine in Healthy Chinese SubjectsCompletedPhase 1Nuance Pharma (shanghai) Co., LtdNCT05758428Written as Ensifentrine
- A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary DiseaseCompletedPhase 2Verona Pharma plcNCT04091360Written as Part A: RPL554
- Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPDCompletedPhase 2Verona Pharma plcNCT03673670Written as RPL554 Suspension
- Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedPhase 2Verona Pharma plcNCT03443414Written as RPL554 suspension
- The Effects of RPL554 in Addition to Tiotropium in COPD PatientsCompletedPhase 2Verona Pharma plcNCT03028142Written as 1.5 mg RPL554 plus tiotropium
- Comparison of RPL554 With Placebo and Salbutamol in Asthmatic PatientsCompletedPhase 2Verona Pharma plcNCT02427165Written as RPL554
- The Effects of RPL554 on Top of Standard COPD Reliever MedicationsCompletedPhase 2Verona Pharma plcNCT02542254Written as RPL554
- SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD SubjectsCompletedPhase 1Verona Pharma plcNCT02307162Written as RPL554
As the comparator · 1 — what is tested is compared with ensifentrine
Codes
What other systems call ensifentrine · ClinicalTrials.gg INT004961
- MeSH (NLM) C512996ensifentrineConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 3E3D8T1GIXENSIFENTRINEConfirmed FDA, NLM, Wikidata
- Wikidata Q135257708ensifentrineConfirmed FDA, NLM, Wikidata
- Wikidata Q7277486ensifentrine (stereochemically undefined)Confirmed FDA, NLM, Wikidata
- NCI Thesaurus C166674EnsifentrineOne source FDA
- DrugBank DB16157One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C512996 | ensifentrine | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 3E3D8T1GIX | ENSIFENTRINE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q135257708 | ensifentrine | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7277486 | ensifentrine (stereochemically undefined) | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166674 | Ensifentrine | One source FDA |
| DrugBank | DB16157 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.